834 related articles for article (PubMed ID: 25625928)
1. IMA901: a multi-peptide cancer vaccine for treatment of renal cell cancer.
Kirner A; Mayer-Mokler A; Reinhardt C
Hum Vaccin Immunother; 2014; 10(11):3179-89. PubMed ID: 25625928
[TBL] [Abstract][Full Text] [Related]
2. IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy.
Rausch S; Kruck S; Stenzl A; Bedke J
Future Oncol; 2014 May; 10(6):937-48. PubMed ID: 24941980
[TBL] [Abstract][Full Text] [Related]
3. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.
Walter S; Weinschenk T; Stenzl A; Zdrojowy R; Pluzanska A; Szczylik C; Staehler M; Brugger W; Dietrich PY; Mendrzyk R; Hilf N; Schoor O; Fritsche J; Mahr A; Maurer D; Vass V; Trautwein C; Lewandrowski P; Flohr C; Pohla H; Stanczak JJ; Bronte V; Mandruzzato S; Biedermann T; Pawelec G; Derhovanessian E; Yamagishi H; Miki T; Hongo F; Takaha N; Hirakawa K; Tanaka H; Stevanovic S; Frisch J; Mayer-Mokler A; Kirner A; Rammensee HG; Reinhardt C; Singh-Jasuja H
Nat Med; 2012 Aug; 18(8):1254-61. PubMed ID: 22842478
[TBL] [Abstract][Full Text] [Related]
4. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
6. Phase 1 trial of allogeneic gene-modified tumor cell vaccine RCC-26/CD80/IL-2 in patients with metastatic renal cell carcinoma.
Buchner A; Pohla H; Willimsky G; Frankenberger B; Frank R; Baur-Melnyk A; Siebels M; Stief CG; Hofstetter A; Kopp J; Pezzutto A; Blankenstein T; Oberneder R; Schendel DJ
Hum Gene Ther; 2010 Mar; 21(3):285-97. PubMed ID: 19788391
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now?
Bedke J; Stenzl A
Expert Rev Anticancer Ther; 2013 Dec; 13(12):1399-408. PubMed ID: 24215158
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II study of multipeptide cancer vaccine IMA901 after single-dose cyclophosphamide in Japanese patients with advanced renal cell cancer with long-term follow up.
Hongo F; Ueda T; Takaha N; Tamada S; Nakatani T; Miki T; Ukimura O
Int J Urol; 2023 Feb; 30(2):176-180. PubMed ID: 36305687
[TBL] [Abstract][Full Text] [Related]
9. IMA901: a peptide vaccine in renal cell carcinoma.
Bedke J; Stenzl A
Expert Opin Investig Drugs; 2013 Oct; 22(10):1329-36. PubMed ID: 23899354
[TBL] [Abstract][Full Text] [Related]
10. Cancer cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer as vaccines for the treatment of genitourinary malignancies.
Nelson WG; Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Kim M; Weber CE; Baccala AA; Goeman MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF
Cancer Chemother Pharmacol; 2000; 46 Suppl():S67-72. PubMed ID: 10950151
[TBL] [Abstract][Full Text] [Related]
11. Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.
Zhou X; Jun DY; Thomas AM; Huang X; Huang LQ; Mautner J; Mo W; Robbins PF; Pardoll DM; Jaffee EM
Cancer Res; 2005 Feb; 65(3):1079-88. PubMed ID: 15705910
[TBL] [Abstract][Full Text] [Related]
12. Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer.
Aruga A; Takeshita N; Kotera Y; Okuyama R; Matsushita N; Ohta T; Takeda K; Yamamoto M
Clin Cancer Res; 2013 Apr; 19(8):2224-31. PubMed ID: 23479678
[TBL] [Abstract][Full Text] [Related]
13. TroVax in colorectal cancer.
Rowe J; Cen P
Hum Vaccin Immunother; 2014; 10(11):3196-200. PubMed ID: 25483641
[TBL] [Abstract][Full Text] [Related]
14. Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.
Combe P; de Guillebon E; Thibault C; Granier C; Tartour E; Oudard S
Oncoimmunology; 2015 May; 4(5):e1001236. PubMed ID: 26155388
[TBL] [Abstract][Full Text] [Related]
15. Patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells elicit anti-tumor activity: in vitro results and clinical responses.
Zhou J; Weng D; Zhou F; Pan K; Song H; Wang Q; Wang H; Wang H; Li Y; Huang L; Zhang H; Huang W; Xia J
Cancer Immunol Immunother; 2009 Oct; 58(10):1587-97. PubMed ID: 19221746
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial.
Baek S; Kim CS; Kim SB; Kim YM; Kwon SW; Kim Y; Kim H; Lee H
J Transl Med; 2011 Oct; 9():178. PubMed ID: 22013914
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic gene modified cell based cancer vaccines.
Kozłowska A; Mackiewicz J; Mackiewicz A
Gene; 2013 Aug; 525(2):200-7. PubMed ID: 23566846
[TBL] [Abstract][Full Text] [Related]
18. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
Seledtsov VI; Goncharov AG; Seledtsova GV
Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of granulocyte-macrophage colony-stimulating factor and interleukin-2 as immune adjuvants for a melanoma peptide vaccine.
Block MS; Suman VJ; Nevala WK; Kottschade LA; Creagan ET; Kaur JS; Quevedo JF; McWilliams RR; Markovic SN
Melanoma Res; 2011 Oct; 21(5):438-45. PubMed ID: 21697748
[TBL] [Abstract][Full Text] [Related]
20. Antitumor effect on murine renal cell carcinoma by autologous tumor vaccines genetically modified with granulocyte-macrophage colony-stimulating factor and interleukin-6 cells.
Kinoshita Y; Kono T; Yasumoto R; Kishimoto T; Wang CY; Haas GP; Nishisaka N
J Immunother; 2001; 24(3):205-11. PubMed ID: 11394497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
